|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Review of hybrid electric powered aircraft,its conceptual design and energy management methodologies显示文摘The paper overviews the state-of-art of aircraft powered by hybrid electric propulsion systems.The research status of the design and energy management of hybrid aircraft and hybrid propulsion systems are further reviewed.The first contribution of the review is to demonstrate that,in the context of relatively underdeveloped electrical storage technologies,the study of mid-scale hybrid aircraft can contribute the most to both theoretical and practical knowledge.Meanwhile,the profits and potential drawbacks of applying hybrid propulsion to mid-scale hybrid airplanes have not been thoroughly illustrated.Secondly,as summed in the overview of design methodologies,the multi-objective optimization transcends the single-objective one.The potential of the hybrid propulsion system can be thoroughly evaluated in only one optimization run,if several objectives optimized simultaneously.Yet there are few researches covering the conceptual design of hybrid aircraft using multi-objective optimization.The review of the most popular energy management strategies discloses the third research gap—current methodologies favoured in hybrid ground vehicles do not consider the aircraft safety.Additionally,both non-causal and causal energy management are needed for performing a complicated flight mission with several sub-tasks. | Ye XIE Al SAVVARISAL Antonios TSOURDOS Dan ZHANG Jason GU | 2021 | Chinese Journal of Aeronautics2021，34，4： | 5 |
| 2 | Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV:a phase 2 trial显示文摘The increased coronavirus disease 2019(COVID-19)breakthrough cases pose the need of booster vaccination.We conducted a randomised,double-blinded,controlled,phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated COVID-19 vaccine(BBIBP-CorV)followed by a recombinant protein-based vaccine(NVSI-06-07),using homologous boost with BBIBP-CorV as control.Three groups of healthy adults(600 individuals per group)who had completed two-dose BBIBP-CorV vaccinations 1–3 months,4–6 months and≥6 months earlier,respectively,were randomly assigned in a 1:1 ratio to receive either NVSI-06-07 or BBIBP-CorV boost.Immunogenicity assays showed that in NVSI-06-07 groups,neutralizing antibody geometric mean titers(GMTs)against the prototype SARS-CoV-2 increased by 21.01–63.85 folds on day 28 after vaccination,whereas only 4.20–16.78 folds of increases were observed in control groups.For Omicron variant,the neutralizing antibody GMT elicited by homologous boost was 37.91 on day 14,however,a significantly higher neutralizing GMT of 292.53 was induced by heterologous booster.Similar results were obtained for other SARS-CoV-2 variants of concerns(VOCs),including Alpha,Beta and Delta.Both heterologous and homologous boosters have a good safety profile.Local and systemic adverse reactions were absent,mild or moderate in most participants,and the overall safety was quite similar between two booster schemes.Our findings indicated that NVSI-06-07 is safe and immunogenic as a heterologous booster in BBIBP-CorV recipients and was immunogenically superior to the homologous booster against not only SARS-CoV-2 prototype strain but also VOCs,including Omicron. | Nawal Al Kaabi Yun Kai Yang Jing Zhang Ke Xu Yu Liang Yun Kang Ji Guo Su Tian Yang Salah Hussein Mohamed Saif ElDein Shuai Shao Sen Sen Yang Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Ning Liu Fu Jie Shen Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2022 | Signal Transduction and Targeted Therapy2022，7，7： | 2 |
| 3 | Treatment and prevention of hep- arin-induced thrombocytopenia:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence- based clinical practice guidelines显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，，： | 1 |
| 4 | Absorption in sepsis显示文摘 | Rpnco GL Brendolan AL Dan MA | 2000 | Kidney Interna-tional2000，76，： | 1 |
| 5 | Absoption in sepsis 显示文摘 | Rpnco GL Brandolan AL Dan MA | 2002 | Kidney Int2002，，： | 1 |
| 6 | Absorption in sepsis显示文摘 | Rpnco GL Brendolan AL Dan MA | 2000 | Kidney Int2000，，： | 1 |
| 7 | Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 8 | Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 9 | Experimental study of effect of Ganyanping on fibrosis in rat liver 显示文摘 | TANG WX DAN ZI YAN HM el al | 2003 | World J Gastroenterol2003，9，6： | 1 |
| 10 | Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal ad ministration of a 26-a mino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants显示文摘 | Gaofu Q Dan M Jie W el al | 2004 | Vaccine2004，22，2324： | 1 |
| 11 | Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and preven- tion of thrombosis,9th ed: American College of Chest Physicians evi- dence-based clinical practice guidlines 显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 12 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial显示文摘 | Lars Wallentin Salim Yusuf Michael D Ezekowitz Marco Alings Marcus Flather Maria Grazia Franzosi Prem Pais Antonio Dans John Eikelboom Jonas Oldgren Janice Pogue Paul A Reilly Sean Yang Stuart J Connolly | 2010 | The Lancet . 2010 (9745)2010，，9745： | 1 |
| 13 | Treatment and prevention ofheparin-Induced thrombocytopenia: Antithrombotic Therapy and Pre-vention of Thrombosis,9th ed:American College of Chest PhysiciansEvidence-Based Clinical Practice Guidelines显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 14 | User's guides to the medical literature:how to decide on the applicability of clinical trail results to your patient显示文摘 | Dans AL Dans LF Guyalt GH | 1999 | JAMA1999，282，： | 1 |
| 15 | Mineralogy and geochemistry of boehmite-rich coals:New insights from the Haerwusu Surface Mine,Jungar Coalfield,Inner Mongolia,China显示文摘 | DAI SHIFENG LI DAN CHOU CHENLIN ET AL | 2008 | International Journal of Coal Geology2008，74，34： | 1 |
| 16 | Post natal development of radial glia and the ven tricular zone (VZ):a continuum of the neural stem cell compartment显示文摘 | AnthonyDT José M G Dan AL | | 0，，： | 1 |
| 17 | Treatment and preventionof heparin-induced thrombocytopenia : Antithrombotic Therapy andPrevention of Thrombosis, 9 th ed: American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines 显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 18 | Concomitantuse of antiplatelet therapy with dabigatran or warfarin inthe Randomized Evaluation of Long-TermAnticoagulationTherapy ( RE-LY ) trial 显示文摘 | Dans AL Connolly SJ Wallentin L | 2013 | Circulation2013，127，5： | 1 |
| 19 | Treatment and prevention of hepafin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 显示文摘 | Linkins LA Dans AL Moores LK | 2012 | Chest2012，141，2： | 1 |
| 20 | Inhibition of pyruvate-ferrodoxin oxidoreductase gene expression in Giardia lamblia by a virus-mediated hammerhead ribozyme显示文摘 | Dan M Wang AL Wang CC | 2000 | Mol Microbiol2000，36，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员